NDLI: Adjunctive use of atypical antipsychotics for treatment-resistant generalized anxiety disorder.

Please wait, while we are loading the content...

Insulin glargine and cancer risk: an opinion statement of the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy.

The essential research curriculum for doctor of pharmacy degree programs.

Year: 2010 Volume: 30 Issue: 8

Year: 2010 Volume: 30 Issue: 7

Year: 2010 Volume: 30 Issue: 7 Part 2

Year: 2010 Volume: 30 Issue: 6

Year: 2010 Volume: 30 Issue: 6 Part 2

Year: 2010 Volume: 30 Issue: 5

Year: 2010 Volume: 30 Issue: 5 Part 2

Year: 2010 Volume: 30 Issue: 4

Year: 2010 Volume: 30 Issue: 3

Year: 2010 Volume: 30 Issue: 2

Year: 2010 Volume: 30 Issue: 1

Year: 2009 Volume: 29

Year: 2008 Volume: 28

Year: 2007 Volume: 27

Year: 2006 Volume: 26

Year: 2004 Volume: 24

Year: 2003 Volume: 23

Year: 2002 Volume: 22

Adjunctive use of atypical antipsychotics for treatment-resistant generalized anxiety disorder.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Lorenz, Raymond A. Jackson, Cherry W. Saitz, Marianne
Description	Country affiliation: United States Author Affiliation: Lorenz RA ( Department of Pharmacy Practice, Harrison School of Pharmacy, Auburn University, Auburn, Alabama, USA. lorenz@auburn.edu)
Abstract	Generalized anxiety disorder (GAD) is a common, chronic mental illness that has a significant burden on the patient's quality of life. Treatment for GAD routinely consists of monotherapy with a proven anxiolytic such as an antidepressant or benzodiazepine, but many patients do not respond fully to these drugs, and additional treatment may be needed. Therefore, we reviewed the safety and efficacy of atypical antipsychotics as adjunct therapy to standard GAD pharmacotherapy in patients deemed treatment resistant. We performed a literature search of the MEDLINE database for English-language articles published from January 1966-May 2009. Identified articles were evaluated, and only open-label trials and randomized controlled trials (RCTs) were included in the review. Relevant references from the articles were also evaluated. Only a few reports of large-scale RCTs that assessed an atypical antipsychotic for treatment-resistant GAD have been published. Articles were found for five of the eight currently available atypical antipsychotics, but not for asenapine, clozapine, and paliperidone. Several open-label trials and smaller RCTs support the need for further evaluation of aripiprazole and quetiapine for treatment-refractory GAD, although one quetiapine trial demonstrated negative results. There is disparate data for risperidone, with one open-label trial and one small RCT showing positive results and one large RCT showing negative results. One open-label trial of ziprasidone and one RCT of olanzapine both showed beneficial effects of the drugs. Adverse effects were specific to each agent, with weight gain being the most common, but many studies did not monitor systematically for lipid level, weight, or glucose level changes. Although data suggest efficacy regarding the use of atypical antipsychotics for augmentation of treatment-refractory GAD, more rigorous studies (large, double-blind, placebo-controlled trials) on the safety and efficacy of these agents are needed in order to recommend their use in patients with GAD.
File Format	HTM / HTML
ISSN	02770008
Issue Number	9
Volume Number	30
e-ISSN	18759114
Journal	Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Language	English
Publisher	Wiley-Blackwell
Publisher Date	2010-09-01
Publisher Place	United States
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Pharmacology Antipsychotic Agents Therapeutic Use Anxiety Disorders Drug Therapy Adverse Effects Aripiprazole Benzodiazepines Clinical Trials As Topic Dibenzothiazepines Drug Resistance Humans Piperazines Quetiapine Fumarate Quinolones Randomized Controlled Trials As Topic Risperidone Serotonin Uptake Inhibitors Thiazoles Journal Article Review
Content Type	Text
Resource Type	Article
Subject	Pharmacology (medical)

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

A systematic review of cardiovascular effects after atypical antipsychotic medication overdose.

The use of atypical antipsychotics after traumatic brain injury.

Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis.

Antipsychotics in pregnancy.

Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed.

Psychopharmacology of chronic pain: a focus on antidepressants and atypical antipsychotics.

Atypical antipsychotics in the treatment of delirium. (Journal: Psychiatry and Clinical Neurosciences Volume: 67 Issue: 5)

Did CATIE influence antipsychotic use?

Evidence-based use of second-generation antipsychotics in a state Medicaid pediatric population, 2001-2005.

Adjunctive use of atypical antipsychotics for treatment-resistant generalized anxiety disorder.

Similar Documents

A systematic review of cardiovascular effects after atypical antipsychotic medication overdose.

The use of atypical antipsychotics after traumatic brain injury.

Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis.

Antipsychotics in pregnancy.

Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed.

Psychopharmacology of chronic pain: a focus on antidepressants and atypical antipsychotics.

Atypical antipsychotics in the treatment of delirium. (Journal: Psychiatry and Clinical Neurosciences Volume: 67 Issue: 5)

Did CATIE influence antipsychotic use?

Evidence-based use of second-generation antipsychotics in a state Medicaid pediatric population, 2001-2005.

Adjunctive use of atypical antipsychotics for treatment-resistant generalized anxiety disorder.